437 related articles for article (PubMed ID: 27307536)
1. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
Nash P; Mease PJ; McInnes IB; Rahman P; Ritchlin CT; Blanco R; Dokoupilova E; Andersson M; Kajekar R; Mpofu S; Pricop L;
Arthritis Res Ther; 2018 Mar; 20(1):47. PubMed ID: 29544534
[TBL] [Abstract][Full Text] [Related]
7. Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.
Izumiyama T; Mori Y; Oizumi I; Hamada S; Kurishima H; Terui H; Omori-Shimada R; Yamasaki K; Itoi E
J Orthop Surg (Hong Kong); 2021; 29(2):23094990211012286. PubMed ID: 33938296
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.
Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ
Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429
[TBL] [Abstract][Full Text] [Related]
9. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
Xu Y; Li Y; Dong M; Gao Z; Chen X; Liu H; Shen M
Rheumatology (Oxford); 2020 Dec; 59(12):3657-3665. PubMed ID: 33038239
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.
van der Heijde D; Landewé RB; Mease PJ; McInnes IB; Conaghan PG; Pricop L; Ligozio G; Richards HB; Mpofu S
Arthritis Rheumatol; 2016 Aug; 68(8):1914-21. PubMed ID: 27014997
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis.
Dokoupilová E; Aelion J; Takeuchi T; Malavolta N; Sfikakis PP; Wang Y; Rohrer S; Richards HB
Scand J Rheumatol; 2018 Jul; 47(4):276-281. PubMed ID: 29458278
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.
Kavanaugh A; Mease PJ; Reimold AM; Tahir H; Rech J; Hall S; Geusens P; Wang Z; Pricop L; Mpofu S;
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):347-355. PubMed ID: 27696786
[TBL] [Abstract][Full Text] [Related]
18. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Ligozio G; Mpofu S
J Rheumatol; 2014 Mar; 41(3):414-21. PubMed ID: 24429175
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
Tlustochowicz W; Rahman P; Seriolo B; Krammer G; Porter B; Widmer A; Richards HB
J Rheumatol; 2016 Mar; 43(3):495-503. PubMed ID: 26834211
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inhibitors in psoriatic arthritis.
Mantravadi S; Ogdie A; Kraft WK
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]